Tagrisso, with chemotherapy, reduced the risk of disease progression or death by 38% by investigator assessment vs. Tagrisso monotherapy. Median progression-free survival was 25.5 months in Tagrisso ...

New study results presented at the European Lung Cancer Congress, ELCC, 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s (AZN) Tagrisso, as monotherapy and as the backbone for novel ...

AstraZeneca AZN announced that the European Commission (EC) has approved its blockbuster lung cancer drug, Tagrisso (osimertinib) for expanded use in a lung cancer indication. The EC has now approved ...

(RTTNews) - AstraZeneca (AZN) announced positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial, demonstrating that TAGRISSO (osimertinib) combined with ...

Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by ...

It’s now official: Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against AstraZeneca’s standard-of-care Tagrisso as a first-line treatment ...

Ontario is the first province to fund Tagrisso for patients with non-small cell lung cancer, and Calquence for patients with previously untreated mantle cell lymphoma MISSISSAUGA, ON, Jan. 23, 2026 ...

AstraZeneca unveiled promising new data for two of its cancer drugs — Enhertu and Tagrisso — giving the pharma giant the chance yet again to dominate the stage at the 2024 American Society of Clinical ...

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed ...